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A Quantitative Perspective on Surface Marker
Selection for the Isolation of Functional Tumor Cells
Supplementary Issue: Breast Cancer Detection and Screening
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ABSTR ACT: Much effort has gone into developing fluid biopsies of patient peripheral blood for the monitoring of metastatic cancers. One common
approach is to isolate and analyze tumor cells in the peripheral blood. Widespread clinical implementation of this approach has been hindered by the current choice of targeting epithelial markers known to be highly variable in primary tumor sites. Here, we review current antigen-based tumor cell isolation
strategies and offer biological context for commonly studied cancer surface markers. Expression levels of the most common markers are quantitated for three
breast cancer and two non-small cell lung cancer (NSCLC) lineage models. These levels are contrasted with that present on healthy peripheral blood mononuclear cells (PBMC) for comparison to expected background levels in a fluid biopsy setting. A key feature of this work is establishing a metric of markers
per square micrometer. This describes an average marker density on the cell membrane surface, which is a critical metric for emerging isolation strategies.
These results serve to extend expression of key tumor markers in a sensitive and dynamic manner beyond traditional positive/negative immunohistochemical
staining to guide future fluid biopsy targeting strategies.
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Introduction

From the first observation of tumor cells in the peripheral
blood of cancer patients in 1869,1 researchers have sought
to establish the clinical relevance of finding these abnormal
cells in circulation. Efforts have aimed toward developing a
fluid biopsy in which patient-derived peripheral blood could be
analyzed for circulating tumor cells (CTCs) with the goal of
providing diagnostic and prognostic information with a minimally invasive procedure. While a correlative link between
the presence of tumor cells in circulation and metastatic progression has been shown, 2–5 the current clinical utility of fluid
biopsies remains questionable because of a lack of reliability
and versatility to detect heterogeneous cancer cell types.6,7
Recent evidence suggests that multiple, distinct populations can arise from a single primary tumor with drastically
variable phenotypic profiles.8–10 While the exact mechanisms
that generate and sustain these populations remain an area of
intense research, it has been proposed that metastatic cells can
be generally categorized as either: 1) primary epithelial tumor
cells spilling into circulation through leaky vasculature or
2) primary tumor cells that have lost their epithelial nature
and have actively migrated into the peripheral blood in a

Published by Libertas Academica. Learn more about this journal.

mesenchymal state. Once in systemic circulation, little is
known about the biological functionality and fate that leads
to colonization of metastatic foci at distant sites. Practically,
functional characterization of CTCs has been encumbered by
the extreme rarity at which they are seen of ~1/million. Further, many CTC isolation methods currently available require
fixation and intracellular staining to determine epithelial
identity, which prevents further examination of behavior and
functionality after sorting. In order to fully bridge our understanding of the mechanisms that allow an epithelial cancer
cell to survive in circulation and eventually spread the disease,
viability of these rare cell populations must be preserved during enrichment. Thus, isolation must be based exclusively on
unique surface receptors on the cell membrane that do not disrupt or compromise the integrity of the cell membrane.
In this study, we seek to quantify the surface expression
level of these critical markers on common cell lines. This
work represents a critical step in assessing the opportunities
and limitations of isolating functional tumor-associated cells
from peripheral blood. We have chosen tumor cell lines, as
the majority of clinical research has centered on the utility of
finding epithelial cells in circulation. Finally, we discuss the
Breast Cancer: Basic and Clinical Research 2015:9(S1)
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significant limitations of using these in vitro cell models for
CTCs in the study of rare cancer cell biology.

Current Technologies for Tumor Cell Isolation

Affinity-based separation is a microfluidic technique that
achieves separation through the specific binding of cells to
biomolecules immobilized within a microfluidic channel.
Characteristic surface proteins have high affinity for the molecules, typically antibodies, that coat the channel walls and
allow specific cell capture, while all other cells in the sample
pass through without binding.11 Nagrath et al develop this
concept to separate viable CTCs from peripheral whole blood
samples. CTCs are sorted using a microchip containing
channel posts coated with antibodies against epithelial cell
adhesion molecule (EpCAM).12 Choi et al use microfluidic
channels to allow cells to roll along the channel walls in an
alternate direction of the bulk fluid flow. HL60 cells that
express P-selectin glycoprotein ligand-1 bind to P-selectincoated chips that allow specific capture, while preserving high
viability compared to unsorted controls.13 While this technique has shown promise for enrichment of viable cell populations, it has yet to be employed for epithelial CTC isolation.
Magnetic cell sorting or magnetically actuated cell sorting (MACS®, trademark of Miltenyi Biotec GmbH) is a
sorting technique that relies on magnetic labeling of antigen
positive populations. Magnetic beads are functionalized with
specific antibodies that bind with surface proteins on the targeted cells. Once the targeted cells bind with the magnetic
beads, the solution is placed in a magnetic field to separate
the attached cells, and then the field is removed to collect
the desired cells.11 This method is capable of either batch or
continuous flow processes and can separate up to 1011 cells in
30 minutes.14 For samples with low concentrations of target
cells, the purity of the isolated cells can be very low when compared to other separation techniques. Owen and Sykes show
that for an initial target cell concentration of 1%, the enriched
sample results in 37% purity of the target cell.15 Owing to the
low purities commonly achieved with magnetic sorting, this
technique has commonly been used as a pre-enrichment step
in conjunction with fluorescence activated cell sorting (FACS).
FACS is a microfluidic sorting method that was developed in the late 1960s and has become a standard clinical cell
analysis tool. FACS involves fluorescently labeling specific
proteins on cell surfaces, analyzing the cells individually, and
then sorting into recepticles.16,17 Modern machines are now
capable of sorting based on 12 colors simultaneously along
with two scattering parameters, forward scattering for size
and fluorescent scattering.16 Takao et al use FACS following magnetic pre-enrichment to isolate CTCs from whole
blood. Enrichment was performed by positive selection using
EpCAM microbeads and then analyzed using FACS where
the mean detection efficiency was .95% with only a mean of
3% decrease in cell viability.18 However, the ability of the cells
to be separated depends on the ability to fluorescently tag the
2
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surface of the cell. The level of surface marker expression is
ultimately a determining factor for sorting performance.
CellSearch® is the only FDA-approved method of CTC
isolation for clinical prognosis that couples immunomagnetic
enrichment with fluorescent staining of characteristic markers. CellSearch is specifically designed for the detection and
enumeration of CTCs. The enrichment of these cells begins
with magnetic sorting for EpCAM. The enriched population is then permeabilized and fluorescently labeled for cytokeratin and leukocyte common antigen (CD45) expressions
to further confirm cell identity.19 Clinical studies have shown
statistical significance with prognosis and the number of
CTCs detected for breast, prostate, and colorectal cancers.2,4,20
The cutoff concentration for determining poorer prognosis in metastatic breast cancer and metastatic prostate cancer
is $5 CTCs/7.5 mL of peripheral blood and $3 CTCs/7.5 mL
of peripheral blood in metastatic colorectal cancer. Enumeration of CTCs above the cutoff has shown a significantly lower
progression-free survival time and overall survival time than
patients with fewer CTCs than the cutoff.19,20 While CellSearch is effective for the detection and enumeration of CTCs,
it does not isolate viable cells. This limitation stems from the low
purity after the immunomagnetic enrichment, requiring confirmation of CTC status by intracellular cytokeratin staining.
While antigen-based isolation methods have shown
the greatest promise toward a clinically useful fluid biopsy,
these strategies are critically dependent on the level of antigen
expression presented on target cells. Low quantities, and more
specifically low densities, of the target marker will decrease the
net binding recognition of antibodies to a marker positive cell
surface, potentially leading to poor discrimination between
positive and negative events. Critically, the current literature
poorly describes the expression of even the best-known tumor
markers on the most commonly studied tumor cell lines. Typically, the expression of a marker is communicated as positive
or negative. At best, papers will communicate relative levels in
terms of dim, moderate, bright, or variable. Alternatively, the
level of receptor expression is given as moles of receptor per
mass of cell lysate. Techniques that have been used to detect
cell antigens qualitatively and quantitatively include enzyme
immunoassay (EIA) and enzyme-linked immunosorbent
assay (ELISA).21,22 However, these techniques that quantify
expression on a total mass basis are minimally useful in the
development of viable cell sorting, as they report antigens that
may be present only intracellularly and unavailable for targeting on an intact, viable cell.23,24

Cancer-associated Surface Biomarkers

Since most primary tumors are epithelial in nature, epithelial
markers are commonly targeted for isolation of tumor cells
in peripheral blood. Of these, the EpCAM is by far the
most prevalent in literature. EpCAM is a calcium ionindependent protein that is responsible for homophilic cellto-cell adhesion, 25 and it has been shown to be overexpressed
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in breast cancer specimens by 100–1000-fold relative to the
normal tissue.26 A critical limitation of isolation based on
EpCAM is the prevalence of both EpCAM negative tumor
sites and loss of epithelial markers on cancer cells during the
transition to the more invasive, mesenchymal phenotype.
Particularly in breast cancer, molecular classification of
cancer subtype is conventionally based on human epidermal
growth factor receptor 2 (HER2), estrogen receptor (ER),
and progesterone receptor (PR). These molecules are commonly targeted for breast cancer therapies, and their expression is used in both therapy selection and prognosis. HER2
is a tyrosine kinase that forms heterodimers with epidermal
growth factor receptor (EGFR), HER3, or HER4 to promote cell division.27,28 ER binds the hormone estrogen, where
ligand binding stimulates the proliferation of mammary cells.
Overexpression of ER is hypothesized to contribute to breast
cancer progression through increased cell division and DNA
production and/or formation of genotoxic by-products. 29 PR
is a hormone receptor that is activated by the progesterone
ligand and is a transcription protein for the regulation of specific genes.30 Some studies suggest that expression of PR is
controlled by expression of ER.31
CD44 expression has been widely shown to correlate with
cancer metastasis. CD44 is a transmembrane adhesion receptor that primarily binds to the glycosaminoglycan hyaluronan
in the extracellular matrix 32 and exhibits several different tissue-specific isoforms. Activation of CD44 by hyaluronan has
been observed to stimulate intracellular signaling of cellular
functions such as adhesion, migration, and invasion, which
are key functions in cancer metastasis and progression.33,34 A
recent study showed elevated counts of CD44 +/CD24 - CTCs
in samples of metastatic breast cancer patients.9
E-Cadherin is a transmembrane, calcium-dependent,
homotypic cell-to-cell adhesion protein. The decreased
expression of this adhesion molecule is the first step in the
progression of metastatic cancer by allowing the detachment
of cells from the primary site35 and is a hallmark of epithelialto-mesenchymal transitions.36 Like E-cadherin, N-cadherin
is a calcium-dependent, homotypic cell-to-cell adhesion molecule. However, N-cadherin expression is indicative of invasive and metastatic breast cancers.37,38 While N-cadherin is
an adhesion molecule, it is believed to be responsible for the
attachment as well as the detachment of cancer cells from
the primary tumor and to the distant tissue.37 The increased
expression of N-cadherin is often coupled with the decrease of
E-cadherin in the transition of the epithelial-to-mesenchymal
phenotype, which is commonly referred to as cadherin switch.38
Integrins are a family of cell surface adhesion proteins
involved in the attachment of cells to the extracellular matrix
and play key roles in migration, survival, and activation of apoptosis suppresors.39 In particular, integrin αVβ3 has been identified as a key player in tumor growth, invasion, early angiogenic
activity, and metastasis.40 αVβ3 binds several ligands from the
extracellular matrix, positively regulates cell migration, and is

overexpressed in breast cancer metastatic lesions.41 ICAM-1
is another cancer-associated42,43 surface adhesion molecule
that plays a role in morphology, cell-to-cell interactions, and
cell migration.44 These roles of ICAM-1 along with its positive expression found in CTCs suggest that this protein is
intimately involved in metastasis by controlling the movement of cells through the extracellular matrix.44 In addition
to invasive potential, the proliferation and angiogenic potential of tumor cells are critical to disease progression. EGFR is
a transmembrane protein that belongs to the same family of
tyrosine kinases as HER2. EGFR is a ligand activated by both
epidermal growth factor (EGF), and transforming growth factor-alpha (TGF-α), which ultimately controls processes such as
proliferation, angiogenesis, and inhibition of apoptosis.45 Positive expression of EGFR in breast carcinomas has been linked
to poorer prognosis over EGFR-negative tumors.46

Methods

Cell culture. Three breast cancer cell lines and two nonsmall cell lung cancer (NSCLC) cell lines were cultured. Breast
cancer lines included MDA-MB-231 (mammary adenocarcinoma), MCF-7 (mammary adenocarcinoma), and T-47D
(mammary ductal carcinoma), and NSCLC lines included
A549 (alveolar adenocarcinoma) and H358 (bronchioalveolar carcinoma). All tumor lines were cultured in RPMI-1640
growth medium (HyClone) supplemented with 2.05 mM
l-glutamine, 10% fetal bovine serum (FBS; Fisherbrand), and
1% penicillin-streptomycin (Sigma-Aldrich) and maintained
at 5% CO2 in air and 37°C. Cells were cultured for 48 hours
and were approximately 60–80% confluent just before experimentation. Additionally, a peripheral blood control sample
was graciously provided by Dr. Hainsworth Shin and processed within an hour of collection. Briefly, whole blood was
mixed with a dextran/NaCl solution to a working concentration of 2 wt% dextran and 0.3 wt% NaCl and was allowed
to separate by 1 × g sedimentation at room temperature for
one hour. The buffy coat containing peripheral blood mononuclear cells (PBMC) was then pipetted off and exposed to
red blood cell lysis buffer (155 mM NH4Cl, 10 mM KHCO3,
0.1 mM EDTA) for five minutes to further remove red blood
cells from the sample. The nucleated cells were collected by
centrifugation at 300 × g for five minutes and washed twice
with cold 1 × phosphate-buffered saline (PBS).
Cell imaging. Representative bright field, phase-contrast
images of all tumor cell lines were taken with a Nikon Ti-U
inverted microscope.
Surface marker immunostaining. Tumor cells were
incubated with trypsin/EDTA (0.25%) solution for three
minutes to allow for detachment, rinsed with growth medium,
and centrifuged. Cell concentration and cell diameter were
determined optically with a Cellometer automated cell counter (Nexcelom). Each data replicate sample consisted of 1 × 105
cells in a microcentrifuge tube. For experimentation, a rinsing
buffer of 1 × PBS with 3% FBS was prepared and used for all
Breast Cancer: Basic and Clinical Research 2015:9(S1)
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rinsing steps. All materials and cell samples were kept on ice
throughout the staining procedure. For immunolabeling, cell
samples were first rinsed once with rinsing buffer and centrifuged (400 × g, 1.5 minutes). Subsequently, samples were
incubated with primary antibodies at ~0.5 μg in 150 μL of
rinsing buffer for 40 minutes. For all cell lines, markers were
targeted with primary monoclonal mouse IgG antibodies with
the corresponding isotype controls that consisted of CD326/
EpCAM (IgG2b, clone 9C4, BioLegend), HER1/EGFR
(IgG1, clone AY13, BioLegend), CD44 (IgG1, clone BJ18,
BioLegend), E-cadherin (IgG1, clone 67A4, BioLegend),
erbB2/HER2 (IgG1, clone 24D2, BioLegend), N-cadherin
(IgG1, clone8C11, BioLegend), αVβ3 integrin (IgG1, clone
23C6, BioLegend), ICAM-1 (IgG1, clone HA58, eBioscience, San Diego, CA), and ER-α (IgG2a, clone F-10, Santa
Cruz Biotechnology). Samples were then rinsed twice with
rinsing buffer on ice, with centrifugation between rinses.
Cells were then labeled with biotinylated goat anti-mouse IgG
antibody (Vector Labs) at a 1:400 dilution in rinsing buffer on
ice for 40 minutes. Cells were rinsed twice with rinsing buffer and incubated with streptavidin (SA)-phycoerythrin (PE)
at ~1 μg in 200 μL on ice for 20 minutes. Samples were rinsed
three times and resuspended in ~200 μL rinsing buffer for
immediate analysis.
Flow cytometry. Cell sample immunofluorescence was
assessed with an Accuri C6 flow cytometer. Samples were
kept on ice and then gently vortexed before a cytometry run.
For each replicate, 5000 cell events were collected based on
initial cell culture control gating. PE fluorescence data were
collected for each sample in the FL2 channel configured for
excitation with a 488-nm laser, and emission was detected
through a 585/40 bandpass filter.
Data analysis. Data are calculated as mean ± standard
error of the mean (s.e.m.) (N = 3) for all marker quantification assays and cell diameter calculations. Standard deviation
within individual replicates is also reported in Supplementary
Figure 3. The calibration of QuantiBRITE PE bead was performed every day of cell immunofluorescence data collection,
and fluorescence calibration values were collected in channel FL2. PE per cell values were calculated using a linear

calibration curve (R 2 = ~0.98) of number of PE molecules vs.
FL2 fluorescence generated from the bead calibration of each
on their respective days of collection (Supplementary Fig. 1).
Statistical analysis consisted of a two-tailed student’s t-test
performed in Matlab to calculate P-values (Supplementary
Table 1).

Results

Imaging analysis. A summary of cell types and the corresponding cell sizes is shown in Table 1. From a regression
analysis relating mean forward scatter and mean Cellometer
cell size, cell diameters of individual populations of lymphocytes, monocytes, and granulocytes were extrapolated. As
expected, these PBMC showed diameters smaller than epithelial cancer cells. To estimate cell surface area, a spherical
model was assumed for each cell. While some cell types can
possess membrane folds that can alter diameter and surface
area in certain scenarios47 (e.g. activation of white blood cells),
we posit this simple model is sufficient to generally show accessible marker densities on the surface of the cells studied here.
For morphological comparison, representative bright field
images of tumor cell lines are shown in Figure 1. The basallike breast line MDA-MB-23148 shows morphology quite distinct from any other investigated in the study, with elongated,
multi-polar behavior and favoring minimal cell–cell contact
consistent with basal subtypes. Luminal breast lines MCF-7
and T-47D49 and NSCLC line H358 show morphology more
consistent with an epithelial phenotype favoring extensive
cell–cell contact and colonization. NSCLC line A549 appears
to exhibit behavior somewhere between these extremes with
less organized cell junctions.
Quantitation of marker expression by flow cytometry. The results of marker quantitation using the flow cytometric QuantiBRITE bead assay are presented in Figures 2
and 3, where PE fluorescence serves as a reporter for antigen
quantity. Expression data are presented here as expression fold
over isotype controls as well as normalized to the calculated
mean surface area for each cell type. Because we employed
an indirect immunostaining approach, some labeling amplification inherent in antibody binding interactions was seen.

Table 1. Summary of cell types analyzed in the study. Diameter and surface area calculations are reported as mean ± s.e.m.
CELL TYPE

DESCRIPTION

DIAMETER (µm)

SURFACE AREA (µm2)

MDA-MB-231

Mammary adenocarcinoma

11.5 ± 0.3

415 ± 19

MCF-7

Mammary adenocarcinoma

17.1 ± 0.4

922 ± 43

T-47D

Mammary ductal carcinoma

14.5 ± 0.3

663 ± 34

A549

Alveolar adenocarcinoma

15.0 ± 0.4

710 ± 38

H358

Bronchioalveolar carcinoma

16.8 ± 0.5

890 ± 47

Peripheral lymphocytes

Healthy PBMC

6.7 ± 0.1

142 ± 1

Peripheral monocytes

Healthy PBMC

7.9 ± 0.1

197 ± 2

Peripheral granulocytes

Healthy PBMC

8.2 ± 0.1

209 ± 1

4
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Figure 1. Representative bright field micrograph images of cultured breast cancer lines (MDA-MB-231, MCF-7, T-47D) and NSCLC lines (A549, H358).

In Supplementary Figure 2, a biotin anti-EpCAM primary
was labeled in parallel to biotin-anti-mouse secondary staining, with a 1.3-fold amplification seen for secondary immunolabeling. Further, we also expect some amplification at the
biotin/SA-PE labeling interaction. Although this may skew
the representation of the actual number of biological copies of
these surface proteins, the focus of our study was to provide a
methodology engineering perspective on the maximum level
of antigen affinity recognition afforded by traditional immunolabeling for viable CTC isolation, where some amplification
is not only acceptable but desired. Moreover, as all markers
were tagged with identical indirect staining approaches, relative expression across cell lines and between markers should
be consistent regardless of any labeling amplification.
Overall, marker expression levels often varied drastically between cell lines with some correlation seen between
cell morphology, behavior, and marker profiles. Specifically,
MDA-MB-231 showed significantly decreased PE labeling
density for EpCAM and E-cadherin compared to MCF-7,
T-47D, and H358 (P-values , 0.001), while showing higher
levels of labeling density for CD44, EGFR, and ICAM-1
(P-values # 0.01, Fig. 3). A549 also showed decreased
EpCAM and E-cadherin density (P-values , 0.001) and
increased CD44 density over MCF-7, T-47D, and H358
(P-values , 0.01). EGFR and ICAM-1 expression seemed
to be consistently high, resulting in PE label densities equal
to or greater than 100/μm 2 for all cell lines except MCF-7.
EGFR has been linked to a basal-like molecular signature,50
and elevated levels of EGFR and ICAM-1 have been linked to
metastatic disease.44,51 The αV-β3 integrin is elevated 10-fold
in MDA-MB-231 cells compared to the other tumor lines

investigated (P-values , 0.001), with ~30 PE molecules per
square micrometer. Of particular interest for breast cancer
lines was ERα and HER2 expression because of their prominent clinical role in breast cancer classification, prognosis,
and therapy selection. The antibody chosen (clone F-10, Santa
Cruz Biotechnology) targeted the c-terminus ligand binding
domain. All three breast cancer lines showed a slight increase
in ERα expression over isotype controls (P-values , 0.05,
Fig. 2A–C) and a statistical elevation in expression over
NSCLC lines (P-values , 0.05), which showed virtually no
ERα expression, with the exception of MCF-7 compared
to A549 (P = 0.15, Fig. 2D and E). HER2 expression was
expressed at relatively high levels in all three breast cancer
lines as well as NSCLC lines, resulting in roughly 50–100 PE
molecules per square micrometer (Fig. 3).
Our study also sought to provide background expression levels on PBMC for comparison, as it is ultimately a
determining factor in marker selection for isolating CTCs
from peripheral blood. Figure 2F shows marker expression
fold over IgG for separately gated lymphocyte, monocyte,
and granulocyte populations. Notably, relatively elevated
levels of both CD44 and ICAM-1 are seen. In Figure 3F,
the PE binding density is reported for PBMC, showing high
non-specific noise in isotype controls, especially for monocytes. This immunolabeling noise can reduce the biorecognition contrast between the target tumor cells for capture
and the majority PBMC; hence, here we further demonstrate
the PE labeling density fold vs. peripheral blood monocyte
expression, which represents the most likely culprits for
false-positive capture (Fig. 4). First, MDA-MB-231 showed
drastically attenuated EpCAM (P = 0.0038) and E-cadherin
Breast Cancer: Basic and Clinical Research 2015:9(S1)

5

Cahall et al

0&)






)

,&$0

(5DOSKD

,&$0

(5DOSKD

+(5

(FDGKHULQ

&'

(S&$0

(5DOSKD

,&$0

D9ELQWHJULQ

1FDGKHULQ

+(5

(FDGKHULQ

&'


(*)5


(S&$0



(*)5







D9ELQWHJULQ



+

D9ELQWHJULQ



)ROG,J*



(

1FDGKHULQ

$





1FDGKHULQ

'

7'

+(5

(S&$0

(5DOSKD

,&$0

D9ELQWHJULQ

1FDGKHULQ

+(5


(FDGKHULQ


&'



(*)5



(FDGKHULQ



&'



(*)5

)ROG,J*



&

)ROG,J*

%

0'$0%

(S&$0

)ROG,J*

$

3%0&
/\PSKRF\WHV



(5DOSKD

,&$0

D9ELQWHJULQ

1FDGKHULQ

+(5

(FDGKHULQ

(5DOSKD

,&$0

D9ELQWHJULQ

1FDGKHULQ

+(5


(FDGKHULQ


&'



(*)5



&'



(*)5



*UDQXORF\WHV



(S&$0

)ROG,J*



(S&$0

)ROG,J*

0RQRF\WHV

Figure 2. Summary of tumor marker expression on viable cells. Presented as fold over isotype controls for cancer lines and healthy PBMC as quantified
by flow cytometry analysis of a PE reporter label. All data are reported as mean ± s.e.m.
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Figure 3. Summary of PE labeling density (number of PE molecules per square micrometer of cell surface) for various tumor marker targeting conditions
on viable cancer line cells and healthy PBMC. All data are reported as mean ± s.e.m. The corresponding antibody isotypes are as follows—IgG1: EGFR,
CD44, E-cadherin, HER2, N-cadherin, aVb3 integrin, ICAM-1; IgG2a: ER-alpha; and IgG2b: EpCAM.
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Figure 4. Summary of PE labeling density of all cancer lines studied
presented as fold expression over healthy monocytes from a peripheral
blood sample. Data are reported as mean ± s.e.m.

(P = 0.90) elevation over monocytes because of low expression
seen in Figure 3A. EGFR contrast remains high for MDAMB-231 and NSCLC lines (P-values , 0.01). Although
CD44 and ICAM-1 were highly expressed across all cancer
lines in the study, the contrast over blood cells is reduced
because of the corresponding high expression in PBMC.
MDA-MB-231 has a slight CD44 contrast over monocytes,
and MDA-MB-231 and A549 both retain high contrast for
ICAM-1 expression (P-values , 0.01). Finally, N-cadherin
and αV-β3 integrin expression on all five cancer lines investigated shows little-to-no elevation over that of peripheral
monocytes.

Discussion

Here, we have reported quantitative results of levels of antibody-mediated recognition attained for several commonly
investigated markers associated with metastasis on both breast
cancer and NSCLC lines. To our knowledge, very little information is reported on the numbers of marker proteins present
on cancer cell membrane surfaces. While many fundamental
biology questions can be answered with immunohistochemical
and blotting assays that yield binned positive/negative
information, these approaches generally fail to represent the
highly dynamic and variable expression patterns seen for
many tumor cells.24,52,53 Particularly for antibody-based cell
isolation methodologies, the ability to capture a marker-presenting cell among a majority of marker-negative cells is critically dependent on the amount of marker proteins available
on the cell surface for labeling. In this light, we propose that
these findings represent a significant step toward providing
the tumor cell isolation community with quantitative antigenic expression information.
8
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Notably, our results show distinct expression signatures
for basal and luminal breast cancer subtypes consistent with
the characteristics commonly associated with each. Basal-like
cells are often seen to be more highly invasive and dedifferentiated, while luminal-type cells are often considered epithelial like.49,50 MDA-MB-231 are classified as basal, whereas
MCF-7 and T-47D are luminal A subtypes. We found that
MDA-MB-231 showed elevated levels of mesenchymal and/
or metastatic markers CD44, N-cadherin, αV-β3 integrin,
and ICAM-1 as well as upregulation of EGFR (commonly
seen for basal subtypes) (Fig. 2A).50 Further, the basal-like
MDA-MB-231 also showed lower expression of epithelial
markers EpCAM and E-cadherin compared to MCF-7 and
T-47D (Fig. 2A–C). Elevated levels of mesenchymal markers have been linked to a more metastatic phenotype, as these
proteins play key functional roles as tools for migration and
invasion.54 In the context of CTC isolation that currently
is predominantly based on EpCAM+ sorting, these results
highlight a disconnection between marker targeting strategy
and the biological tendencies of highly invasive cells. Specifically, a detection threshold of EpCAM expression exists for
any antibody-based isolation methodology, and highly invasive cells downregulate EpCAM and have a higher potential
to go unseen as false negatives.
A surprising result was also seen for ERα expression
in comparing the basal (MDA-MB-231) and luminal A
(MCF-7 and T-47D) subtypes in the study. All three cell
lines showed a similar expression of HER2, which was not
unexpected for basal and luminal A subtypes that generally
do not have overexpression of HER2.49 However, we found
that MDA-MB-231 cells also expressed similar surface densities of ERα compared to MCF-7 and T-47D. One possible
explanation could be that because our focus was to determine
antigen densities on intact tumor cell surfaces, the antibody
chosen for ERα targeting (clone F-10, Santa Cruz Biotech)
targeted the C-terminal ligand binding domain; however,
these nuclear receptors are often trafficked intracellularly.55
Therefore, these results do not account for intracellular ERα
where differences in expression between basal and luminal A
subtypes could arise.
Our study also sought to offer some order-of-magnitude
perspective on expression levels of surface markers CD44,
N-cadherin, αV-β3 integrin, and ICAM-1 implicated in
metastatic progression, 39,44,56 as these could potentially serve
as promising new targets for sorting clinically relevant cells. A
poorly expressed molecule may play an important role biologically, but would be of minimal utility as a target for live cell isolation. Furthermore, a molecule may even be highly expressed,
but if it is also highly expressed on peripheral blood cells, it
would no longer serve to distinguish epithelial identity from
the background blood cells. PBMC marker expression was
normalized to cell size similar to epithelial cells, and PBMC
size estimates were found to be in fair agreement with literature.57,58 We found that although both N-cadherin and αV-β3
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integrin were upregulated on some lines (MDA-MB-231 and
A549), their inherent expression density was still approximately equal to or below the expression found on peripheral
monocytes, which consistently showed the highest background
staining levels (Figs. 3F and 4). Additionally, while CD44 was
relatively high for all cancer lines (Fig. 3), it was also highly
expressed in PBMC, which reduced the expression ratio over
monocytes to nearly 1 or below for all lines except MDAMB-231 that retained a seven-fold ratio over monocytes (Fig.
4). Therefore, because our results show minimal differences in
expression of these markers over blood cells, they are not recommended for targeting intact tumor cells. It is worth noting
though that more work is warranted in quantitating the extent
of elevation of markers like N-cadherin, which are shown to
undergo a cadherin switch from stromal cytokine stimulation in vivo.59,60 This phenotypic transition is correlated with
a more invasive cell and could conceivably potentiate N-cadherin as a target for tumor cell isolation. ICAM-1 expression
density was seen to be approximately 30-to-60-fold higher
than monocytes for T-47D and MDA-MB-231, respectively
(Fig. 4). ICAM-1 is involved in cell adhesion interactions and
migration and has been recently been classified as a mesenchymal cell marker.61–63 Further, one recent study has shown
that increased populations of ICAM-1high CTCs correlated to
poorer prognosis in hepatocellular carcinoma patients.44 Coupled with these findings, our results point toward ICAM-1 as
a potential target for isolation of clinically relevant tumor cells.
In conclusion, we have reported surface marker densities
on several model tumor cell lineages to guide the development
of isolation methodologies for live and functional CTC populations. The surface density of targeted markers is a critical
parameter for any antigen-based CTC capture platform and
likely represents a key oversight that has led to poor performance of many previously developed technologies. Our results
also indicate extreme variability in expression between markers
and cancer cell lines and illustrate the need for greater appreciation of heterogeneity at the surface marker level across different
cancer subsets. While the values in Figures 2 and 3 are presented
as mean ± s.e.m, Supplementary Figure 3 also shows that the
variance in immunofluorescence for cell events within each replicate was often considerably higher. This could be due in part
to the inherent variability within the cultured cell population as
well as deviations from the mean Kd for each antibody used. As
with any antibody-based assay, the variance in antibody binding affinity from different suppliers should be carefully considered when interpreting these data as well as in designing an
antibody-based isolation strategy. Further, cancer heterogeneity
has also been widely reported for in vivo settings.53,64 Cytokine
signaling and tumor–stromal interactions can cause certain
subsets of malignant cells to display drastically altered marker
profiles, some resembling stem-like phenotypes in what is
referred to as epithelial–mesenchymal transition.8 These highly
potent subsets have been reported to go largely unnoticed in
EpCAM based isolation strategies, leading many to suggest

that perhaps EpCAM alone is not sufficient to capture any and
all CTCs.6,65 Our findings further support that EpCAM surface presentation cannot be assumed to be similar for all tumor
lines, and more comprehensive targeting strategies that account
for expression-level variability is warranted. One possible
strategy would be to use panels of antibodies to target several
tumor markers to ensure successful capture in instances where
certain markers are downregulated. For example, Yu et al targeted patient-derived breast CTCs with a cocktail of EpCAM,
EGFR, and HER2 antibodies in a microchip device approach,
where subsequent fluorescent immunostaining of captured
cells revealed that they possessed highly variable and dynamic
phenotypes with both epithelial and mesenchymal markers.52
Building upon these types of robust targeting strategies will be
vital for developing future generations of more clinically relevant fluid biopsy technologies.
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